ADORA3 and liver disorder: Nevertheless, the A3AR selective agonists Piclidenoson and Namodenoson have progressed into clinical trials for treating inflammatory diseases, including rheumatoid arthritis, psoriasis, and liver diseases such as hepatocellular carcinoma, hepatitis, and dry eye syndrome16–22.